ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 815.9 USD | 0.00% |
|
0.00% | 0.00% |
| 06-07 | Jefferies Adjusts Price Target on Eli Lilly to $957 From $925 | MT |
| 06-07 | US FDA Staff Flags Potential Limited Benefit of Eli Lilly's Alzheimer's Disease Drug | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 42.98B 3,379B | Sales 2025 * | 52.62B 4,137B | Capitalization | 765B 60,163B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 938B | Net income 2025 * | 16.55B 1,301B | EV / Sales 2024 * | 18.2 x |
| Net Debt 2024 * | 18.07B 1,420B | Net Debt 2025 * | 15B 1,179B | EV / Sales 2025 * | 14.8 x |
| P/E ratio 2024 * |
63.6
x | P/E ratio 2025 * |
45.8
x | Employees | 43,000 |
| Yield 2024 * |
0.61% | Yield 2025 * |
0.71% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +4.55% | ||
| 1 month | +7.31% |
1 week
815.90
815.90
1 month
760.30817.60
Current year
760.30817.60
1 year
760.30817.60
3 years
760.30817.60
5 years
760.30817.60
10 years
760.30817.60
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 15/10/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 815.9 | 0.00% |
| 05/06/24 | 815.9 | 0.00% |
| 04/06/24 | 815.9 | 0.00% |
| 03/06/24 | 815.9 | 0.00% |
| 31/05/24 | 815.9 | +6.65% |
End-of-day quote Lima, June 05, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B | |
| -0.73% | 162B |
